No abstract available.
Exanthema* ; Skin*

No abstract available.
Child* ; Exanthema* ; Humans ; Skin*

No abstract available.
Bacillus ; Exanthema ; Immunotherapy ; Pityriasis

Coronavirus Disease 2019 (Covid-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is recognized as a worldwide public health crisis. It has rapidly spread from Wuhan City in China after an outbreak of flu-like illness. Respiratory symptoms remain the most common manifestation of Covid-19. However, dermatologic manifestations have been observed in patients with COVID-19 infection. Kulkharni, et al. published a case report of morbilliform rashes as a probable herald of Covid-19 being its initial and only manifestation of COVID-19.1 This is a case of a 45-year-old female who presented with worsening morbilliform rashes on both upper extremities and was initially diagnosed with allergic contact dermatitis. She had no respiratory symptoms and was eventually diagnosed with Covid-19 in a routine Reverse Transcription Polymerase Chain Reaction test (RT-PCR). She was subsequently admitted for treatment and recovered after 2 weeks of hospital stay.
Covid-19 ; Exanthema

Allopurinol is the well-known first-line treatment option for symptomatic hyperuricaemia and gout. It is cost-effective particularly for the management of chronic gout. The common early side effects of allopurinol are skin rashes, diarrhoea and nausea. Meanwhile, a dangerous concerning complication is Stevens–Johnson syndrome, which can cause severe morbidity and mortality. Delayed hypersensitivity to allopurinol is rare but should be one of the differential diagnoses if a patient with underlying gout on chronic allopurinol treatment presents with skin rashes. The present case highlights the importance of a high index of suspicion in at-risk patients with underlying gout along with skin rashes on long-term allopurinol treatment to avoid unnecessary patient management.
Hypersensitivity, Delayed ; Allopurinol ; Exanthema

As anti-tumor necrosis factor alpha (anti-TNFalpha) agents are progressively being used in various medical conditions, dermatological adverse events have been encountered more frequently. To understand such dermatological conditions that have been documented while undergoing anti-TNF therapy, we reviewed relevant literature, including case reports and case series. Reported dermatological conditions included infusion and injection site reaction, cutaneous infection, psoriasiform eruption, dermatitis, allergic rash, lupus-like lesion, vasculitis, lichenoid reaction, granulomatous reaction, hair loss, cutaneous infection, and cutaneous neoplasm. These events had varying strengths of causal association and severity therefore, drug discontinuation may or may not be required.
Dermatitis ; Exanthema ; Hair ; Necrosis* ; Vasculitis

No abstract available.
Diagnosis* ; Exanthema* ; Lymphadenitis* ; Scrub Typhus*

Summary Cutaneous manifestations of Coronavirus disease (COVID-19) are variable. We present a case of non-drug related symmetrical flexural and intertriginous exanthema in a patient with COVID-19 infection. A 58-year-old Chinese male who was diagnosed to have COVID-19 infection, developed maculopapular erythematous rashes at bilateral axillary and inguinal folds on the fourth day of illness. He was treated symptomatically with anti-histamine and topical corticosteroid. The skin condition improved and he was discharged well on tenth day of illness. Although symmetrical flexural intertriginous exanthema isclassically caused by drug reaction, this case demonstrated the possibility of the rash being directly associated with COVID-19 infection. More cohorts should be evaluated to fully describe the full spectrum of dermatological manifestation in COVID-19.
Exanthema ; COVID-19 ; Skin Manifestations

Cough ; Exanthema ; Fever ; Humans ; Respiratory Sounds

BACKGROUND:To evaluate the efficacy of lamotrigine on bipolar disorder, both manic and depressed episode, the author compared the effects of lamotrigine with lithium and placebo. METHOD: Forty-seven manic patients with bipolar disorder and 43 depressed patients with bipolar disorder were treated with lamotrigine, lithium or placebo during 6 weeks. Their severity of symptoms were rated weekly using Young's Rating Scale for Mania and Hamilton Rating Scale for Depression. RESULTS: In manic patients the therapeutic efficacy of lamotrigine was lower than that of lithium during baseline to week 2, but after week 3, lamotrigine was as effective as lithium. In depressed patients the therapeutic efficacy of lamotrigine was superior to lithium from week 2 to endpoint. Most patients tolerated well except that one patient developed skin rashes. CONCLUSION: Lamotrigine seems to have antimanic and antidepressant effect as lithium in the treatment for acute bipolar disorder.
Bipolar Disorder* ; Depression ; Exanthema ; Humans ; Lithium*